Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Maniscalco (Telese (BN), Italy), A. Detoraki (Napoli (NA), Italy), M. D’Amato (Napoli (NA), Italy), R. Giacco (Napoli (NA), Italy), C. Calabrese (Napoli (NA), Italy), . Boccia (Napoli (NA), Italy), E. Tremante (Napoli (NA), Italy), R. Poto (Napoli (NA), Italy), G. Quaremba (Napoli (NA), Italy), G. Spadaro (Napoli (NA), Italy). Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study. 2215

Member's Comments

No comment yet.

Related content which might interest you: Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Effect of mepolizumab on chronic rhinosinusitis symptoms and nasal hypersensitivity in patients with or without nasal polyps Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities Year: 2020 Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020 Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma: results from a phase 2a trial Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP) Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Aspirin-induced urticaria/angioedema without respiratory symptoms in severe asthmatics with nasal polyposis Source: Eur Respir J 2002; 20: Suppl. 38, 512s Year: 2002 Impact of mepolizumab in severe asthma with nasal polyps Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 The prevelance of chronic nasal symptoms in COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 264s Year: 2002 Effect of anti-IL5 treatment on symptoms of chronic rhinosinusitis, otitis and hearing loss in patients with severe eosinophilic asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Effect of FESS on asthma patients with nasal polyposis and chronic sinusitis Source: International Congress 2016 – Clinical studies in asthma and immunology Year: 2016 Quality of life, clinical symptoms and nasal obstruction in patients with allergic rhinitis Source: Eur Respir J 2003; 22: Suppl. 45, 418s Year: 2003 Patient characteristics and treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Canada Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD Year: 2018 Nasal budesonide ameliorates symptoms and polysomnography findings in children with chronic nasal obstruction and mild sleep-disordered breathing Source: Eur Respir J 2003; 22: Suppl. 45, 391s Year: 2003